Pharma channel feed

Need a place­bo con­trol group for your next can­cer drug study? On­ly in cer­tain cir­cum­stances, says FDA

7 years ago

Sang­amo re­searcher charged with in­sid­er trad­ing in lat­est round of SEC ac­cu­sa­tions lev­eled at a biotech ex­ec

7 years ago
People

Once laud­ed for its clin­i­cal suc­cess, Roche casts off car­dio pro­gram in­clacum­ab for a mere $2M to Glob­al Blood Ther­a­peu­tics

7 years ago

TCR deal fren­zy con­tin­ues as blue­bird antes up $30M for new Grit­stone al­liance

7 years ago

Os­teoarthri­tis: FDA drafts guid­ance on de­vel­op­ing drugs, de­vices, bi­o­log­ics

7 years ago

Bris­tol-My­ers will sell Op­di­vo in Chi­na at half of US cost, set­ting prece­dent for check­point wave — re­port

7 years ago
China

Re­mem­ber mo­melo­tinib? Gilead un­loads shelved JAK in­hibitor for to­ken $3M pay­ment from its for­mer de­vel­op­ers

7 years ago

Costs ris­ing, As­traZeneca switch­es con­trac­tors and once again de­lays sched­uled com­ple­tion of its trou­bled $650M-plus HQ project

7 years ago

No­vo Nordisk turns to Evotec to build ear­ly-stage pipeline for di­a­betes, obe­si­ty drugs

7 years ago

$60M in, Ab­b­Vie is trig­ger­ing a $625M-plus plan to de­vel­op a new im­muno-on­col­o­gy drug that is go­ing af­ter GARP

7 years ago

FDA turns thumbs down on Al­ler­gan's op­ti­mistic case for uter­ine fi­broid drug as liv­er dam­age threat tor­pe­does ap­pli­ca­tion

7 years ago
R&D

As­traZeneca’s on­col­o­gy drug star Tagris­so gets a new ap­proval for front­line lung can­cer in Japan

7 years ago

FDA gives Mer­ck ‘re­al-time’ OK for Keytru­da, of­fer­ing a peek at the lat­est ex­ten­sion of the agen­cy's da­ta ex­press high­way

7 years ago

Har­bour Bio­Med jumps in­to the crowd­ed PD-1/L1 race, look­ing to take a Chi­nese as­set glob­al as check­point pipeline bulges

7 years ago
R&D
China

Roche picks up a speedy nod in Chi­na as reg­u­la­tors fol­low through on plans for a fast 48 new drug OKs

7 years ago
China

Out­spo­ken re­searcher Pe­ter Bach urges CMS to con­sid­er ways of bring­ing down CAR-T prices — and of­fers a few sug­ges­tions

7 years ago

Just a few days af­ter a stum­ble, FDA OKs 12-week dose for Eylea as Re­gen­eron braces for No­var­tis at­tack

7 years ago

In a land­mark OK, FDA green-lights Bris­tol-My­er­s' Op­di­vo for a niche group of metasta­t­ic lung can­cer pa­tients

7 years ago

FDA, NIH look to stream­line over­sight of gene ther­a­pies

7 years ago
Cell/Gene Tx

Months af­ter team­ing up on RTK in­hibitor Lenvi­ma, Ei­sai/Mer­ck win new FDA OK in liv­er can­cer

7 years ago

Af­ter a years-long de­lay, FDA ap­proves first gener­ic ver­sions of EpiPen

7 years ago

No more hands-off Roche su­per­vi­sion? Genen­tech brings out the axe, slash­ing 223 HQ staffers 'across de­part­ments'

7 years ago
R&D

Pfiz­er hits the gas ped­al in the mR­NA flu vac­cine de­vel­op­ment race, ink­ing a $425M in­vest­ment pact with BioN­Tech

7 years ago

Eyes on Chi­na stocks: Lon­car loads new ETF with his picks for most promis­ing biotechs on HKEX and Nas­daq

7 years ago
China
First page Previous page 290291292293294295296 Next page Last page
A service from the Financial Times